Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study.
- DOI
- 10.1016/j.clml.2021.12.010
- Published
- 2021-12-24
- Container
- Clin Lymphoma Myeloma Leuk
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.clml.2021.12.010,
title = {Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study.},
author = {Palomba ML and Till BG and Park SI and Morschhauser F and Cartron G and Marks R and Shivhare M and Hong WJ and Raval A and Chang AC and Penuel E and Popplewell LL.},
year = {2022},
journal = {Clin Lymphoma Myeloma Leuk},
doi = {10.1016/j.clml.2021.12.010},
url = {https://doi.org/10.1016/j.clml.2021.12.010}
}RIS
TY - JOUR TI - Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study. AU - Palomba ML AU - Till BG AU - Park SI AU - Morschhauser F AU - Cartron G AU - Marks R AU - Shivhare M AU - Hong WJ AU - Raval A AU - Chang AC AU - Penuel E AU - Popplewell LL. PY - 2022 JO - Clin Lymphoma Myeloma Leuk DO - 10.1016/j.clml.2021.12.010 UR - https://doi.org/10.1016/j.clml.2021.12.010 ER -
APA
ML, P., BG, T., SI, P., F, M., G, C., R, M., M, S., WJ, H., A, R., AC, C., E, P., & LL., P. (2022). Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study.. Clin Lymphoma Myeloma Leuk. https://doi.org/10.1016/j.clml.2021.12.010
Source records
- europe-pmc · retrieved 2026-09-25T20:20:35.899Z
- hal · retrieved 2026-09-25T20:20:35.941Z